Is Solazyme the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Solazyme (Nasdaq: SZYM  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Solazyme.


What We Want to See


Pass or Fail?

Growth 5-Year Annual Revenue Growth > 15% 248.2%* Pass
  1-Year Revenue Growth > 12% 2.6% Fail
Margins Gross Margin > 35% 93.8% Pass
  Net Margin > 15% (138.3%) Fail
Balance Sheet Debt to Equity < 50% 8.4% Pass
  Current Ratio > 1.3 8.86 Pass
Opportunities Return on Equity > 15% (33.8%) Fail
Valuation Normalized P/E < 20 NM NM
Dividends Current Yield > 2% 0% Fail
  5-Year Dividend Growth > 10% 0% Fail
  Total Score   4 out of 9

Source: S&P Capital IQ. NM = not meaningful due to negative earnings. Total score = number of passes. * Three-year growth rate.

With only four points, Solazyme isn't close to perfection just yet. The biofuel maker is on the cutting edge of an interesting technology, but it has a ways to go before becoming profitable.

The biofuels industry has gotten extremely popular in recent years. As oil prices have risen, the possibilities for alternative fuels have become more feasible. Already, Solazyme is working with Chevron (NYSE: CVX  ) on biodiesel technology, while Dow Chemical (NYSE: DOW  ) has also signed on to develop oils to act as insulating fluids for electrical transformers.

But what truly sets Solazyme apart from its competitors are its non-energy-related oil offerings. The company has a line of beauty products, which has drawn interest from Unilever (NYSE: UL  ) as a strategic investor, as well as specifically designed oils for various food products. With the higher margins available from these lines of business, Solazyme could become profitable a lot sooner than it would otherwise.

Earlier this week, Solazyme made an interesting deal, announcing a joint venture for a Brazilian facility to produce renewable oils with Bunge (NYSE: BG  ) . By tying itself to yet another big partner, Solazyme will be able to provide enough supply to meet rising demand.

For Solazyme to keep improving, it needs to take advantage of these extensive resources to come up with practical solutions with valuable economic uses. Eventually -- and if energy prices stay high -- Solazyme should be able to boost its volume sufficiently to reach profitability. From there, the sky's the limit for Solazyme.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

Solazyme is promising, but if you like energy stocks, we've got another stock idea that could knock your socks off. Read about it right here in The Motley Fool's special free report on the energy industry and its best prospects -- it's free but only available for a limited time, so click here today.

Click here to add Solazyme to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned. The Motley Fool owns shares of Solazyme. Motley Fool newsletter services have recommended buying shares of Chevron and Unilever. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1855026, ~/Articles/ArticleHandler.aspx, 5/3/2016 2:21:56 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated Moments ago Sponsored by:
DOW 17,776.35 -114.81 -0.64%
S&P 500 2,066.94 -14.49 -0.70%
NASD 4,780.25 -37.35 -0.78%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/3/2016 2:06 PM
SZYM $2.34 Down -0.02 -0.85%
Solazyme CAPS Rating: ***
BG $62.04 Down -0.48 -0.77%
Bunge Limited CAPS Rating: ***
CVX $101.16 Down -2.15 -2.08%
Chevron CAPS Rating: ****
DOW $51.78 Down -0.87 -1.65%
The Dow Chemical C… CAPS Rating: *****
UL $45.05 Down -0.27 -0.60%
Unilever CAPS Rating: *****